Clinical trial
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of…
NCT00294515 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00294515 |
|---|---|
| Title | IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients |
| Acronym | IMPACT |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Infections |
| Intervention type | Drug |
| Interventions | Valganciclovir |
| Enrollment | 326 |
| Start date | Mar 31, 2006 |
| Primary completion | Aug 31, 2008 |
| Completion | Aug 31, 2009 |
| First posted | Feb 22, 2006 |
| Last update posted | Mar 29, 2018 |
| Countries | Australia, Belgium, Brazil, Canada, France, Germany, Italy, New Zealand, Poland, Romania, Spain, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: